利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

720 records (took 0.034 seconds)

    Method of performing hemofiltration
    1.
    发明授权
    Method of performing hemofiltration 有权
    进行血液滤过的方法

    公开(公告)号：US08216172B2

    公开(公告)日：2012-07-10

    申请号：US13287683

    申请日：2011-11-02

    Applicant: Peter C. Chang ,  Jean-Michel Lannoy

    Inventor： Peter C. Chang ,  Jean-Michel Lannoy

    IPC: A61M1/34 ,  A61K33/06 ,  A61K33/20 ,  A61K33/42 ,  A61K33/00 ,  A01N1/02

    CPC classification number: A61M1/3672 ,  A61K31/19 ,  A61K33/06 ,  A61K33/14 ,  A61K33/42 ,  A61K45/06 ,  A61M1/3437 ,  A61M1/3458 ,  A61M1/3675 ,  Y10S514/822 ,  A61K2300/00

    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

    Abstract translation: 提供了用于体外血液处理的多部分替代输注液及其使用方法。 通常，多部分取代流体包括由电解质组成但不含二价阳离子的第一溶液和包含二价阳离子的第二溶液。 另一个实施方案包括含有匹配的柠檬酸盐/柠檬酸抗凝剂的第三溶液。 所描述的使用多部分替代输注液的方法显着降低与各种体外血液治疗相关的风险。

    Six-membered heterocycles useful as serine protease inhibitors
    2.
    发明授权
    Six-membered heterocycles useful as serine protease inhibitors 有权
    用作丝氨酸蛋白酶抑制剂的六元杂环

    公开(公告)号：US08163749B2

    公开(公告)日：2012-04-24

    申请号：US12097080

    申请日：2006-12-13

    Applicant: James R. Corte

    Inventor： James R. Corte

    IPC: A01N43/58 ,  A61K31/50 ,  A61K31/44 ,  A61K31/13 ,  C07D221/18 ,  C07D421/00

    CPC classification number: C07D213/40 ,  C07D213/54 ,  C07D213/63 ,  C07D213/64 ,  C07D213/73 ,  C07D213/89 ,  C07D239/26 ,  C07D401/04 ,  Y10S514/822

    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, R3 and R11 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

    Abstract translation: 本发明提供式（I）化合物或其立体异构体，互变异构体，药学上可接受的盐或溶剂合物形式，其中变量A，B，R 3和R 11如本文所定义。 式（I）的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶，因子Xa，因子XIa，因子IXa，因子VIIa和/或血浆激肽释放酶。 特别地，它涉及作为选择性因子XIa抑制剂或fXIa和血浆激肽释放酶的双重抑制剂的化合物。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。

    MULTI-PART SUBSTITUTION INFUSION FLUIDS AND MATCHING ANTICOAGULANTS
    3.
    发明申请
    MULTI-PART SUBSTITUTION INFUSION FLUIDS AND MATCHING ANTICOAGULANTS 有权
    多部分替代输注液和匹配抗凝剂

    公开(公告)号：US20100301268A1

    公开(公告)日：2010-12-02

    申请号：US12831811

    申请日：2010-07-07

    Applicant: Peter C. Chang ,  Jean-Michel Lannoy

    Inventor： Peter C. Chang ,  Jean-Michel Lannoy

    IPC: C09K3/00

    CPC classification number: A61M1/3672 ,  A61K31/19 ,  A61K33/06 ,  A61K33/14 ,  A61K33/42 ,  A61K45/06 ,  A61M1/3437 ,  A61M1/3458 ,  A61M1/3675 ,  Y10S514/822 ,  A61K2300/00

    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

    Abstract translation: 提供了用于体外血液处理的多部分替代输注液及其使用方法。 通常，多部分取代流体包括由电石而不含二价阳离子组成的第一溶液和包含二价阳离子的第二溶液。 另一个实施方案包括含有匹配的柠檬酸盐/柠檬酸抗凝剂的第三溶液。 所描述的使用多部分替代输注液的方法显着降低与各种体外血液治疗相关的风险。

    MULTI-PART SUBSTITUTION INFUSION FLUIDS AND MATCHING ANTICOAGULANTS
    5.
    发明申请
    MULTI-PART SUBSTITUTION INFUSION FLUIDS AND MATCHING ANTICOAGULANTS 有权
    多部分替代输注液和匹配抗凝剂

    公开(公告)号：US20070134348A1

    公开(公告)日：2007-06-14

    申请号：US11678525

    申请日：2007-02-23

    Applicant: Peter Chang ,  Jean-Michel Lannoy

    Inventor： Peter Chang ,  Jean-Michel Lannoy

    IPC: A61K33/42 ,  A61K33/14 ,  A61K31/19

    CPC classification number: A61M1/3672 ,  A61K31/19 ,  A61K33/06 ,  A61K33/14 ,  A61K33/42 ,  A61K45/06 ,  A61M1/3437 ,  A61M1/3458 ,  A61M1/3675 ,  Y10S514/822 ,  A61K2300/00

    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

    Abstract translation: 提供了用于体外血液处理的多部分替代输注液及其使用方法。 通常，多部分取代流体包括由电石而不含二价阳离子组成的第一溶液和包含二价阳离子的第二溶液。 另一个实施方案包括含有匹配的柠檬酸盐/柠檬酸抗凝剂的第三溶液。 所描述的使用多部分替代输注液的方法显着降低与各种体外血液治疗相关的风险。

    Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution
    10.
    发明授权
    Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution 失效
    保持血栓调节素水溶液的质量的方法

    公开(公告)号：US06808706B1

    公开(公告)日：2004-10-26

    申请号：US09509994

    申请日：2000-05-08

    Applicant: Masaki Yui ,  Akira Yokozawa ,  Tomoyo Murata ,  Kazuhisa Tsuruta ,  Hirotomo Shimizu

    Inventor： Masaki Yui ,  Akira Yokozawa ,  Tomoyo Murata ,  Kazuhisa Tsuruta ,  Hirotomo Shimizu

    IPC: C12N900

    CPC classification number: A61K9/0019 ,  A61K38/00 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/44 ,  C07K14/7455 ,  Y10S514/822

    Abstract: A method for keeping the quality of an aqueous parenteral solution of thrombomodulin which is not in a frozen or freeze-dried state but in a liquid form in storage and distribution, characterized in that the aqueous thrombomodulin solution containing an effective amount of soluble thrombomodulin and a buffer component exhibiting a buffering activity in a pH range of 5 to 7.0 has a pH of 5 to 7.0 and that (a) the aqueous thrombomodulin solution further contains a surfactant and is in a state aseptically filled into a case or (b) the aqueous thrombomodulin solution is the form of a prefilled syringe preparation produced by aseptically filling the thrombomodulin solution into a syringe substantially without any empty space. This method provides for the storage and distribution of an aqueous parenteral solution of thrombomodulin in a liquid state for a prolonged period and makes it possible to provide an aqueous parenteral solution which is excellent in long-term stability and shaking stability and can save the trouble of dissolving in use.

    Abstract translation: 一种保持不是冷冻或冷冻干燥状态而是液体形式的血栓调节蛋白的水性肠胃外溶液的储存和分配的质量的方法，其特征在于含有有效量的可溶性血栓调节蛋白和 在5〜7.0的pH范围内表现出缓冲活性的缓冲成分的pH为5〜7.0，（a）血栓调节素水溶液还含有表面活性剂，处于无菌填充状态的状态，或（b） 血栓调节蛋白溶液是通过将基本上没有任何空白空间无菌地将血栓调节蛋白溶液注入注射器而制备的预充式注射器制剂的形式。 该方法提供长时间稳定的液体状态的血栓调节蛋白的肠胃外水溶液的储存和分配，能够提供长期稳定性和摇晃稳定性优异的水性肠胃外溶液，并且可以节省 溶于使用。

Patent Agency Ranking